Navigation Links
Bausch + Lomb Announces Final Results for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)
Date:8/20/2012

ROCHESTER, N.Y., Aug. 20, 2012 /PRNewswire/ -- Bausch & Lomb Incorporated ("Bausch + Lomb") announced today the final results of its previously announced tender offer (the "tender offer") to purchase for cash up to $300 million of its outstanding 9 ⅞ percent Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8) (the "senior notes").

As of the previously announced "expiration date" of 11:59 p.m., New York City time, on August 17, 2012, according to Global Bondholder Services Corporation, which acted as the tender and information agent for the tender offer, $74,691,000 aggregate principal amount of senior notes were validly tendered and not withdrawn.  Bausch + Lomb has accepted for purchase all senior notes that were validly tendered and not withdrawn prior to the expiration date.

Bausch + Lomb is also announcing an extension of the previously announced settlement date for the tender offer, which is now expected to be August 22, 2012.

The complete terms and conditions of the tender offer are described in the Bausch + Lomb Offer to Purchase dated July 23, 2012.  Citigroup served as the dealer manager for the tender offer.

This press release does not constitute an Offer to Purchase or a solicitation of an Offer to Sell our senior notes or other securities, nor shall there be any purchase of senior notes in any state or jurisdiction in which such offer, solicitation or purchase would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The tender offer was made solely by and pursuant to the Bausch + Lomb Offer to Purchase dated July 23, 2012.

About Bausch + Lomb

Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, th
'/>"/>

SOURCE Bausch + Lomb Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bausch + Lomb Announces Extension of Early Tender Date for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)
2. Bausch + Lomb Commences Tender Offer of Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3 and U07190AA6)
3. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
4. Bausch + Lomb Names John Barr Global President Surgical
5. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
6. ShangPharma Announces Second Quarter 2012 Results
7. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
8. Apexigen Announces the Filing of an IND by its Partner, 3SBio
9. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
10. Perrigo Company Announces Quarterly Dividend
11. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... (NASDAQ: PRXL ), a leading global biopharmaceutical ... appointed several executives to its global team of ... in PAREXEL,s PACE™ (Peri-Approval Clinical Excellence) group. This team ... to prove the value of their products to multiple ...
... 2011 Biodesix today announced  that results from a ... phase III study, EGF30008, will be presented at the ... The purpose of the study was to evaluate the ... outcomes following treatment with either Femara ® or Femara ...
Cached Medicine Technology:PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals 2PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals 3PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals 4PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals 5Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 2Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 3
(Date:8/29/2015)... ... 2015 , ... Targeted therapies, made possible by a growing ... according to a newly published report. Surviving Mesothelioma has more on the findings ... The authors of the new paper focus on several types of targeted approaches ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Decatur County Memorial Hospital recently transitioned management companies to partner with Wound Care ... for their outpatient wound center. , Transitioning wound care management providers can ...
(Date:8/28/2015)... ... ... With the goal of furthering music education programs in schools, the “Music ... Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best Drug ... underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best Drug ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... On May ... Michigan, joined as sponsor of the “Music With A Mission” benefit concert in Mendon, ... the event was to raise money to support music education programs in the underfunded ...
Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... A Danish study had reported that children in their teens ... to the harsh glare of the sun. // In the ... researchers had asked 340 volunteers to wear a wristwatch that ... UVR doses. ,The volunteers of the study included ...
... and Japan have been able to identify a type ... //beings awake. By tracking the nerve cells in rats, ... neuron receives inhibitory signals during night that makes them ... a chemical called orexin that keeps the animal awake. ...
... that increased exposure to infections in early infancy, as ... of developing acute lymphoblastic leukemia. ,The study results ... UK of age 2 to 14 yrs without cancer ... acute lymphoblastic leukemia. Day care and social activities were ...
... Medical School said that intake of calcium supplements over ... people at risk of colon cancer.// ,Calcium ... pre-cancerous polyp formations in colon. Calcium has chemo protective ... ,The previous study was in a trial, which ...
... Athletes who drink water during long distance running events ... much water // is almost as bad for health ... says the study researchers of UT Southwestern Medical Center, ... long race may lead to a condition called hyponatremia. ...
... have found out that having green tea catechins for a ... in males.// ,Of the 32 people who were ... only one person developed the cancer. They all had been ... the property of green tea catechins or a component of ...
Cached Medicine News:
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... Calibrated Guide Wires are available in two ... 9 in. length. Material: DePuy certified stainless ... ,Smooth wires etched in 1/2 in. ... also available. Etched in 1/2 in. ...
Kirschner Wires are available in four point styles ranging from .028 to .062 in. Smooth tip wire available in 4, 6 and 9 in. lengths. Threaded tip available. Material: DePuy certified stainless steel...
... Non-Donor Supplemental: Calypte Biomedical ... HIV-1 antibody testing algorithm as well ... Western Blot Kit [Human Immunodeficiency Virus ... products represent a portfolio of established ...
Medicine Products: